Previous Close | 5.33 |
Open | 5.40 |
Bid | 5.14 x 200 |
Ask | 5.38 x 200 |
Day's Range | 5.21 - 5.40 |
52 Week Range | 2.68 - 8.22 |
Volume | |
Avg. Volume | 329,747 |
Market Cap | 164.764M |
Beta (5Y Monthly) | 4.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences. Event:H.C. Wainwright 2nd Annual Cell Therapy ConferencePresentation:March 26, 2024 at 2:00 p.m. ETFormat:Virtual fireside chat and one-on-one meetings Event:Cantor Fitzgerald’s Muscul
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-10